Roche send anti-TIGIT makers higher after cancer drug data
Michael Vi/iStock Editorial via Getty Images Developers of a drug class called anti-TIGIT immunotherapies traded higher in pre-market trading on ...
Michael Vi/iStock Editorial via Getty Images Developers of a drug class called anti-TIGIT immunotherapies traded higher in pre-market trading on ...
AzmanJaka/E+ via Getty Images Arcus Biosciences (NYSE:RCUS) is a biopharmaceutical company specializing in cancer therapeutics that are operating at the ...
Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.